The company's CRISPR platform leverages novel Cas enzymes, which have unique properties that can be used to create CRISPR-based therapeutics and diagnostics for a range of diseases, the company said.

Mammoth said it will focus on Cas14 and Casɸ. These families are the smallest known CRISPR systems.

Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX, Plum Alley, and others participated in the financing round. In 2020, Mammoth raised $45 million in a round of financing that included participation by Amazon.

KromaTiD launches mapping service for human genome in single cells
KromaTiD has launched a new product called dGH Screen for mapping the human genome in single cells. The tool uses the company's proprietary directional...

'Dimmable' switch for gene therapy shows potential for rare diseases
A new alternative splicing system called Xon can modulate levels of protein expression in gene therapy, much like a dimmer switch. The invention addresses...

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...

CRISPR-based method can speed the identification of disease-causing genes
A new CRISPR gene editing screening method can be used to link phenotype and genotype in animal models. The method was efficiently deployed in zebrafish...